Translation, cultural adaptation and validation of the Danish version of the haematological malignancy patient-reported outcome measure (HM-PRO)

Abstract Background Assessment of cancer patients´ quality of life (QoL) through patient-reported outcomes (PRO) during and after treatment is gaining ground. The HM-PRO is the first generic Haematological Malignancy specific PRO measure for use in clinical practice and clinical trials. Such generic...

Full description

Saved in:
Bibliographic Details
Main Authors: Sam Salek, Sören Möller, Niels Abildgaard, Tine Rosenberg, Maria Torp Larsen, Peter Asdahl, Kasper Kofod Pedersen, Marie Therese Lassen, Christen Lykkegaard Andersen, Lene Kongsgaard Nielsen
Format: Article
Language:English
Published: SpringerOpen 2025-04-01
Series:Journal of Patient-Reported Outcomes
Subjects:
Online Access:https://doi.org/10.1186/s41687-025-00869-2
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Assessment of cancer patients´ quality of life (QoL) through patient-reported outcomes (PRO) during and after treatment is gaining ground. The HM-PRO is the first generic Haematological Malignancy specific PRO measure for use in clinical practice and clinical trials. Such generic tools are needed in Denmark. The study aim was to translate and cross-culturally adapt the HM-PRO into Danish and evaluate the psychometric properties. Methods Translation and cross-cultural adaptation of the original English HM-PRO into Danish followed established guidelines. After cognitive debriefing interviews, it underwent psychometric testing with a variety of hematologic malignancies. Construct validity, internal consistency, dimensionality, item response theory (IRT) and differential item functioning were investigated. Results 295 patients were included for psychometric evaluation; confirmatory factor and bifactor analyses for both HM-PRO parts provided good evidence to support the suggested factor structure (Cronbach’s-α Part-A = 0.81, Part-B = 0.84; Part-A CFA CFI = 0.922, TLI = 0.912; bi-factor CFI = 0.989, TLI = 0.978). IRT showed good item-fit and factor loadings and absence of local dependency. Conclusion The HM-PRO has demonstrated favourable psychometric properties and can be used broadly within the Danish Healthcare system to monitor symptoms as well as QoL impact of patients with haematological cancer and optimize patient engagement during routine cancer care. What is the new aspect of your work? In response to the intention of the Danish Health Authority to systematically collect PRO data on health-related QoL in Danish cancer patients, this study investigates the translation and cross-cultural adaptation of the original English HM-PRO into Danish. What is the central finding of your work? Few issues were met with the translation and adaptation of HM-PRO into Danish. What is (or could be) the specific clinical relevance of your work? The HM-PRO has demonstrated favourable psychometric properties and can be used broadly within the Danish Healthcare system to monitor symptoms as well as QoL impact of patients with haematological cancer and optimize patient engagement during routine cancer care.
ISSN:2509-8020